Shelley Brown
Family · Wilmington, NCNPI 1467624205
Payments from drug & device makers
Across 122 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$508
- Novo Nordisk$272
- AstraZeneca$241
- Pfizer$185
- Abbott$108
- Lilly USA, LLC$108
- plus $621 from 16 others
What the payments were for
- Food & beverage$2,044100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $508 |
| Novo Nordisk | 19 | $272 |
| AstraZeneca | 13 | $241 |
| Pfizer | 10 | $185 |
| Abbott | 6 | $108 |
| Lilly USA, LLC | 7 | $108 |
| Exact Sciences | 5 | $90 |
| Astellas Pharma US Inc | 4 | $78 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Amgen | 3 | $48 |
| Boehringer Ingelheim | 3 | $47 |
| Phathom Pharmaceuticals, Inc. | 4 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Bayer | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| GSK | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$2,044 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-100Insulin Degludec | 19 | $8,381 |
| Rosuvastatin Calcium | 47 | $866 |
| Levothyroxine Sodium | 51 | $651 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $650 |
| Atorvastatin Calcium | 62 | $329 |
| Omeprazole | 16 | $193 |
| Ezetimibe | 19 | $192 |
| Metoprolol Succinate | 29 | $189 |
| Pantoprazole Sodium | 20 | $146 |
| Pravastatin Sodium | 13 | $112 |
| Amlodipine Besylate | 42 | $111 |
| Doxycycline Hyclate | 12 | $99 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $98 |
| Lisinopril | 23 | $89 |
| Meloxicam | 15 | $83 |
Paid to pharmacies, not to this prescriber.
Other family in Wilmington
- Teresa DossWilmington$137K
- Courtney WilsonWilmington$81K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.